A mid-size pharmaceutical company approached Eminent Global Research Solutions with a clear challenge  they had a promising oncology portfolio, but limited visibility into which international markets would offer the best commercial opportunities.

The client wanted to avoid a costly “one-size-fits-all” expansion strategy. Instead, they needed a data-driven roadmap to understand where to launch first, how competitors were positioned, and which regions offered the strongest long-term growth potential.

The Challenge

The oncology market is highly competitive and differs significantly across regions. Regulatory timelines, reimbursement systems, treatment adoption, and competitor presence vary from country to country.

The client specifically needed support with:

• Identifying the most attractive global markets
• Understanding oncology demand by region
• Evaluating regulatory complexity and approval timelines
• Benchmarking competitor activity
• Building a phased launch strategy

Our Approach

Our team conducted a comprehensive market intelligence and strategic assessment across key oncology markets in North America, Europe, APAC, and selected emerging economies.

The project included:

• Global oncology market sizing and growth forecasting
• Competitive benchmarking of leading pharma players
• Regulatory pathway and reimbursement analysis
• Identification of underserved oncology segments
• Market attractiveness scoring and prioritization
• Launch sequencing recommendations

Key Insights

Strong Growth Potential in APAC

Several Asia-Pacific markets demonstrated rapid oncology treatment adoption and increasing healthcare investments, making them attractive early-expansion opportunities.

Competitive White Space Opportunities

The analysis revealed niche oncology indications with lower competitive intensity, allowing the client to position strategically before larger players entered.

Regulatory Trade-Offs Across Markets

While some European markets offered favorable reimbursement potential, approval timelines were longer compared to selected emerging markets.

Smarter Launch Sequencing

Rather than launching simultaneously across multiple regions, a phased expansion strategy reduced commercial risk and optimized resource allocation.

Business Impact

The client used the findings to refine its international commercialization roadmap and prioritize high-potential markets with greater confidence.

Outcomes included:

✔ Improved strategic decision-making for global expansion
✔ Faster identification of high-value target markets
✔ Reduced market entry risk through evidence-based prioritization
✔ Better alignment between regulatory strategy and commercial planning
✔ Enhanced visibility into competitor positioning and future pipeline activity